Pfizer, the global drug manufacturer and pharmaceutical company are planning to stop selling their inhaled insulin product Exubera. The news will come as a surprise to many diabetics, as the idea of inhaled insulin was perceived as the holy grail of diabetes treatment until recently.
Pfizer have heavily promoted Exubera in the two years it has been on the market, yet sales of the drug remain tiny. Overall, it accounts for less than 1 per cent of the total insulin market.
The withdrawal of Exubera is expected to cost some $2.8 billion. This renders the entire fiasco one of the most expensive flops in pharmaceutical history. Pfizer, who are the largest drug company in the world, have faced a rocky road recently.
The decision raises greater overall questions about the potential for inhaled insulin to command strong sales and compete with normal injectable insulin. The chairman of Pfizer reportedly concluded: “Despite our best efforts, Exubera has failed to gain the acceptance of patients and physicians.”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…